Viruses (Mar 2023)

Multifactorial White Matter Damage in the Acute Phase and Pre-Existing Conditions May Drive Cognitive Dysfunction after SARS-CoV-2 Infection: Neuropathology-Based Evidence

  • Ellen Gelpi,
  • Sigrid Klotz,
  • Miriam Beyerle,
  • Sven Wischnewski,
  • Verena Harter,
  • Harald Kirschner,
  • Katharina Stolz,
  • Christoph Reisinger,
  • Elisabeth Lindeck-Pozza,
  • Alexander Zoufaly,
  • Marlene Leoni,
  • Gregor Gorkiewicz,
  • Martin Zacharias,
  • Christine Haberler,
  • Johannes Hainfellner,
  • Adelheid Woehrer,
  • Simon Hametner,
  • Thomas Roetzer,
  • Till Voigtländer,
  • Gerda Ricken,
  • Verena Endmayr,
  • Carmen Haider,
  • Judith Ludwig,
  • Andrea Polt,
  • Gloria Wilk,
  • Susanne Schmid,
  • Irene Erben,
  • Anita Nguyen,
  • Susanna Lang,
  • Ingrid Simonitsch-Klupp,
  • Christoph Kornauth,
  • Maja Nackenhorst,
  • Johannes Kläger,
  • Renate Kain,
  • Andreas Chott,
  • Richard Wasicky,
  • Robert Krause,
  • Günter Weiss,
  • Judith Löffler-Rag,
  • Thomas Berger,
  • Patrizia Moser,
  • Afshin Soleiman,
  • Martin Asslaber,
  • Roland Sedivy,
  • Nikolaus Klupp,
  • Martin Klimpfinger,
  • Daniele Risser,
  • Herbert Budka,
  • Lucas Schirmer,
  • Anne-Katrin Pröbstel,
  • Romana Höftberger

DOI
https://doi.org/10.3390/v15040908
Journal volume & issue
Vol. 15, no. 4
p. 908

Abstract

Read online

Background: There is an urgent need to better understand the mechanisms underlying acute and long-term neurological symptoms after COVID-19. Neuropathological studies can contribute to a better understanding of some of these mechanisms. Methods: We conducted a detailed postmortem neuropathological analysis of 32 patients who died due to COVID-19 during 2020 and 2021 in Austria. Results: All cases showed diffuse white matter damage with a diffuse microglial activation of a variable severity, including one case of hemorrhagic leukoencephalopathy. Some cases revealed mild inflammatory changes, including olfactory neuritis (25%), nodular brainstem encephalitis (31%), and cranial nerve neuritis (6%), which were similar to those observed in non-COVID-19 severely ill patients. One previously immunosuppressed patient developed acute herpes simplex encephalitis. Acute vascular pathologies (acute infarcts 22%, vascular thrombosis 12%, diffuse hypoxic–ischemic brain damage 40%) and pre-existing small vessel diseases (34%) were frequent findings. Moreover, silent neurodegenerative pathologies in elderly persons were common (AD neuropathologic changes 32%, age-related neuronal and glial tau pathologies 22%, Lewy bodies 9%, argyrophilic grain disease 12.5%, TDP43 pathology 6%). Conclusions: Our results support some previous neuropathological findings of apparently multifactorial and most likely indirect brain damage in the context of SARS-CoV-2 infection rather than virus-specific damage, and they are in line with the recent experimental data on SARS-CoV-2-related diffuse white matter damage, microglial activation, and cytokine release.

Keywords